AKBA - Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches
2025-08-07 19:34:39 ET
More on Akebia
- Akebia Therapeutics, Inc. (AKBA) Q2 2025 Earnings Call Transcript
- Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026
- Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying
- Akebia Q2 2025 Earnings Preview
- Seeking Alpha’s Quant Rating on Akebia